Gary Sternberg

Biography

Dr. Sternberg's professional career has been focused on integrating medicine and business in order to advance science while also creating value. He brings more than 20 years of ophthalmology expertise including biotechnology and pharmaceutical industry experience, as well as medical practice. His most recent role was as Chief Business Officer of Eleven Biotherapeutics. At Eleven, he completed M&A and licensing transactions, including a licensing transaction for Eleven's anti IL-6 monoclonal antibody (EBI-031) with Roche, targeting the ophthalmic indications of diabetic macular edema and uveitis. The deal brought in $30 million of upfront and near term cash plus potential milestones totaling $240 million plus royalties. He also was the corporate development lead in the acquisition of a late stage oncology company, Viventia Bio, that uses targeted protein therapeutics to treat cancers with high unmet medical need. Prior to Eleven, Dr. Sternberg served as Therapeutic Head of Ophthalmic Medical Affairs for Genentech, Inc. At Genentech, he had responsibility for all facets of US Medical Affairs for the anti-VEGF drug Lucentis (ranibizumab), a transformational drug in the retina area. He was medical monitor for the SHORE study, a post-marketing commitment study in retinal vein occlusion, and also headed a robust investigator sponsored trial (IST) program in support of ophthalmic clinical investigators who were exploring clinical questions that were not adequately addressed in prior clinical trials. Prior to Genentech, he served as Executive Director, Strategic Transactions Group for Bristol-Myers Squibb, as Chief Business Officer for Fovea Pharmaceuticals, an ophthalmic focused biotechnology company, and as Vice President Alliance Management and Business Development for Eyetech Pharmaceuticals Inc. and (OSI) Eyetech, Inc.

Research Interest

 His research interest in Business and Management